http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100530918-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C251-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-38 |
| filingDate | 2003-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100530918-B1 |
| titleOfInvention | Fluorine-Substituted Cathechol N-Methyl Hydrazide Derivatives |
| abstract | The present invention relates to novel catechol N-methylhydrazide derivatives and pharmaceutical compositions containing them. More particularly, the present invention relates to a novel catechol N-methylhydrazide derivative having the structure of Formula 1 and a pharmaceutical composition containing the same. The compound according to the present invention has an inhibitory effect on phosphodiesterase IV or Tumor necrosis factor (TNF), and also has asthma, arthritis, osteoarthritis, bronchitis, chronic airway obstruction disease, psoriasis, allergic rhinitis, dermatitis It is also useful in the treatment of diseases including AIDS, HIV, Crohn's disease, sepsis, septic shock, other inflammatory diseases such as fetal odor, and production of TNF.n n n <Formula 1>n n n n n n n n (In the formula, R 1 to R 3 and Y are the same as defined in the specification.) |
| priorityDate | 2003-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.